WAVE Life Sciences (WVE) Set to Release Earnings on Tuesday

WAVE Life Sciences (NASDAQ:WVE) will likely be releasing its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $4.51 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:30 AM ET.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.04). The business had revenue of $2.27 million for the quarter, compared to analyst estimates of $7.45 million. WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%. On average, analysts expect WAVE Life Sciences to post ($1.12) EPS for the current fiscal year and ($1.29) EPS for the next fiscal year.

WAVE Life Sciences Price Performance

Shares of NASDAQ WVE opened at $3.37 on Thursday. The stock has a market capitalization of $664.67 million, a P/E ratio of -3.09 and a beta of -1.43. The company has a 50-day moving average price of $4.31 and a 200-day moving average price of $5.64. WAVE Life Sciences has a 1 year low of $3.04 and a 1 year high of $21.73.

Insiders Place Their Bets

In other news, Director Adrian Rawcliffe sold 12,700 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total value of $67,183.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Heidi L. Wagner sold 7,000 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total transaction of $42,070.00. Following the completion of the sale, the director owned 44,930 shares of the company’s stock, valued at approximately $270,029.30. This represents a 13.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 23,564 shares of company stock worth $132,476 over the last ninety days. Insiders own 24.34% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on WVE. Wedbush set a $13.00 price target on shares of WAVE Life Sciences in a research report on Friday, October 2nd. Zacks Research downgraded WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. B. Riley Financial decreased their price objective on WAVE Life Sciences from $31.00 to $22.00 and set a “buy” rating for the company in a report on Friday, July 31st. JPMorgan Chase & Co. started coverage on WAVE Life Sciences in a report on Wednesday, September 23rd. They set a “neutral” rating for the company. Finally, William Blair initiated coverage on WAVE Life Sciences in a research note on Friday, October 16th. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, WAVE Life Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.53.

About WAVE Life Sciences

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.